Harrow

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.

Harrow Health

5 Stocks To Watch Heading Into Thursday

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HROW

JAMF

MRSN

RDDT

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

xr:d:DAFkdW1Tf7Y:2,j:2276961543181188932,t:23053105

Movers

IBTA

SMCI

TSHA

TTEK

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

xr:d:DAFfORZ4lNo:2,j:2185570849,t:23040509

BJDX

BURU

CLDI

CYCC

DBGI

EFSH

ELAB

MTNB

QBTS

QUBT

SVMH

XTIA

ZCAR

ZETA

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Harrow Inc

Harrow, Inc. - 8.625% senior notes due 2026

Harrow, Inc. - 11.875% Senior Notes due 2027

Press Releases

Harrow Announces Market Access Wins for VEVYE®

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Harrow Announces Third Quarter 2024 Financial Results

Harrow Announces Participation in Upcoming Investor Conferences

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

GDRX

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

ANI Pharmaceuticals

Arvinas

BGM Group

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Evolus

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Indivior

Innoviva

Liquidia

Maze Therapeutics

Nuvation Bio

Ocular Therapeutix

Omeros

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Tilray Brands

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

HC Wainwright & Co.

Lake Street

Craig-Hallum

B. Riley Securities

Comments

Harrow

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga